VERTEX PHARMACEUTICALS INC / MA Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $4.82 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-13.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2020-02-13
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2019 was $4.82M, a 239.34% increase from fiscal 2018.
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2018 was $1.42M, a 90.73% decline from fiscal 2017.
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2017 was $15.32M, a 37.87% decline from fiscal 2016.
- VERTEX PHARMACEUTICALS INC / MA effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2016 was $24.66M, a 323.98% increase from fiscal 2015.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month as first filed |
|---|---|---|
| 2019-12-31 | $4.82M 10-K · filed 2020-02-13 | |
| 2018-12-31 | $1.42M 10-K · filed 2020-02-13 | |
| 2017-12-31 | $15.32M 10-K · filed 2020-02-13 | $21.82M 10-K · filed 2018-02-15 |
| 2016-12-31 | $24.66M 10-K · filed 2019-02-13 | $24.75M 10-K · filed 2017-02-23 |
| 2015-12-31 | $5.82M 10-K · filed 2018-02-15 | |
| 2014-12-31 | $18.76M 10-K · filed 2017-02-23 | |
| 2013-12-31 | $9.61M 10-K · filed 2016-02-16 | |
| 2012-12-31 | $3.08M 10-K · filed 2015-02-13 | $3.20M 10-K · filed 2013-03-01 |
| 2011-12-31 | $1.95M 10-K · filed 2014-02-11 | |
| 2010-12-31 | $2.16M 10-K · filed 2013-03-01 | |
| 2009-12-31 | $8.24M 10-K · filed 2012-02-22 | |
| 2008-12-31 | $127.00K 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |